Novel Variants in PTPN11 , NF1 , RASA2 , and MAP2K1 : Expanding the Molecular Spectrum of RASopathies in a Turkish Cohort
Clinical Genetics · 2026-07 · 110 (1) · 36-45
DOI: 10.1111/cge.70162 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Genetics, online erschienen am 19.03.2026. Verfasst von Hatice Kocak Eker und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Konya City Hospital, Konya, Turkey. Hauptthemen laut MEDLINE: MAP Kinase Kinase 1, Neurofibromin 1, Protein Tyrosine Phosphatase, Non-Receptor Type 11, ras Proteins. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
RASopathies are a group of genetically heterogeneous developmental disorders caused by germline variants affecting the RAS/MAPK signaling pathway. These disorders display overlapping clinical features and diverse molecular mechanisms. This study aimed to evaluate the clinical and molecular spectrum of patients diagnosed with RASopathies, with a particular focus on novel and rare variants. A retrospective, multicenter study was conducted on patients with clinically suspected RASopathy and diagnosed by targeted Next Generation Sequencing analysis between 2021 and 2024. Variants were classified according to ACMG criteria, and clinical data were reviewed for genotype–phenotype correlations. Among 23 patients (14 males, 9 females), 15 (65.2%) had Noonan syndrome, five (21.7%) Neurofibromatosis Type 1, two (8.7%) Cardio‐facio‐cutaneous syndrome, and one (4.3%) Neurofibromatosis–Noonan syndrome. The most frequent clinical findings were craniofacial dysmorphism (91.3%), musculoskeletal anomalies (82.6%), and cutaneous features (78.3%). A total of 24 heterozygous variants were identified in seven genes: PTPN11 (45.8%), NF1 (25%), LZTR1 (12.5%), and RASA2, SOS1, MAP2K1 , and BRAF (each 4.2%). Four novel variants were detected ( PTPN11 c.853 + 4A>G, RASA2 p.E71D, NF1 p.W784Mfs*10, MAP2K1 p.A106T). This study highlights the clinical and molecular heterogeneity of RASopathies and expands the variant spectrum with novel and rare pathogenic alterations. The identification of new variants, particularly in rarely implicated genes such as RASA2 , underlines the diagnostic value of comprehensive NGS‐based testing and the need for individualized, multidisciplinary clinical management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Genetics, Konya City Hospital, Konya, Turkey.
- Faculty of Medicine, Department of Medical Genetics, Uşak University, Uşak, Turkey.
- Department of Pediatric Endocrinology, Konya City Hospital, Konya, Turkey.
- Department of Medical Genetics, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Turkey.
ORCID-Profile: Hatice Kocak Eker, Tugba Akın Duman, Fahrettin Duymus, Muserref Basdemirci, Busra Eser Cavdartepe, Nurdan Çiftci, Levent Simsek
Zitieren
APA
Kocak Eker, H., Akın Duman, T., Duymus, F., Basdemirci, M., Eser Cavdartepe, B., Çiftci, N., & Simsek, L. (2026). Novel Variants in PTPN11 , NF1 , RASA2 , and MAP2K1 : Expanding the Molecular Spectrum of RASopathies in a Turkish Cohort. Clinical Genetics, 110(1), 36-45. https://doi.org/10.1111/cge.70162
Vancouver
Kocak Eker H, Akın Duman T, Duymus F, Basdemirci M, Eser Cavdartepe B, Çiftci N, et al. Novel Variants in PTPN11 , NF1 , RASA2 , and MAP2K1 : Expanding the Molecular Spectrum of RASopathies in a Turkish Cohort. Clinical Genetics. 2026;110(1):36-45. doi:10.1111/cge.70162
BibTeX
@article{KocakEker2026,
author = {Kocak Eker, Hatice and Akın Duman, Tugba and Duymus, Fahrettin and Basdemirci, Muserref and Eser Cavdartepe, Busra and Çiftci, Nurdan and Simsek, Levent},
title = {Novel Variants in PTPN11 , NF1 , RASA2 , and MAP2K1 : Expanding the Molecular Spectrum of RASopathies in a Turkish Cohort},
journal = {Clinical Genetics},
year = {2026},
volume = {110},
number = {1},
pages = {36--45},
doi = {10.1111/cge.70162}
}
EUVIMED